Vanguard Group’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-47,256
| Closed | -$27.4K | – | 4614 |
|
|
2023
Q1 | $27.4K | Sell |
47,256
-98,463
| -68% | -$78.3K | ﹤0.01% | 4515 |
|
|
2022
Q4 | $102K | Sell |
145,719
-5,641
| -4% | -$9.18K | ﹤0.01% | 4393 |
|
|
2022
Q3 | $422K | Hold |
151,360
| – | – | ﹤0.01% | 4260 |
|
|
2022
Q2 | $688K | Hold |
151,360
| – | – | ﹤0.01% | 4203 |
|
|
2022
Q1 | $1.08M | Sell |
151,360
-18,717
| -11% | -$109K | ﹤0.01% | 4179 |
|
|
2021
Q4 | $1.15M | Sell |
170,077
-224
| -0.1% | -$2.29K | ﹤0.01% | 4229 |
|
|
2021
Q3 | $1.98M | Buy |
170,301
+2,456
| +1% | +$34K | ﹤0.01% | 4055 |
|
|
2021
Q2 | $3.14M | Buy |
167,845
+150,745
| +882% | +$2.81M | ﹤0.01% | 3818 |
|
|
2021
Q1 | $396K | Buy |
17,100
+13,686
| +401% | +$347K | ﹤0.01% | 4168 |
|
|
2020
Q4 | $47K | Buy |
3,414
+1,310
| +62% | +$19.4K | ﹤0.01% | 4184 |
|
|
2020
Q3 | $44K | Hold |
2,104
| – | – | ﹤0.01% | 4072 |
|
|
2020
Q2 | $32K | Hold |
2,104
| – | – | ﹤0.01% | 4046 |
|
|
2020
Q1 | $29K | Hold |
2,104
| – | – | ﹤0.01% | 4030 |
|
|
2019
Q4 | $63K | Buy |
2,104
+810
| +63% | +$19.4K | ﹤0.01% | 4037 |
|
|
2019
Q3 | $20K | Hold |
1,294
| – | – | ﹤0.01% | 4129 |
|
|
2019
Q2 | $32K | Hold |
1,294
| – | – | ﹤0.01% | 4136 |
|
|
2019
Q1 | $47K | Buy |
1,294
+98
| +8% | +$4.03K | ﹤0.01% | 4065 |
|
|
2018
Q4 | $43K | Sell |
1,196
-2,354
| -66% | -$198K | ﹤0.01% | 4083 |
|
|
2018
Q3 | $554K | Buy |
3,550
+1,935
| +120% | +$286K | ﹤0.01% | 3831 |
|
|
2018
Q2 | $216K | Sell |
1,615
-2,278
| -59% | -$344K | ﹤0.01% | 3967 |
|
|
2018
Q1 | $964K | Buy |
3,893
+175
| +5% | +$49.3K | ﹤0.01% | 3655 |
|
|
2017
Q4 | $1.03M | Buy |
3,718
+472
| +15% | +$180K | ﹤0.01% | 3608 |
|
|
2017
Q3 | $1.31M | Sell |
3,246
-199
| -6% | -$104K | ﹤0.01% | 3518 |
|
|
2017
Q2 | $2.04M | Buy |
3,445
+1,317
| +62% | +$770K | ﹤0.01% | 3372 |
|
|
2017
Q1 | $1.31M | Buy |
2,128
+627
| +42% | +$223K | ﹤0.01% | 3511 |
|
|
2016
Q4 | $304K | Sell |
1,501
-570
| -28% | -$130K | ﹤0.01% | 3823 |
|
|
2016
Q3 | $544K | Sell |
2,071
-109
| -5% | -$33.4K | ﹤0.01% | 3743 |
|
|
2016
Q2 | $651K | Buy |
2,180
+69
| +3% | +$24.3K | ﹤0.01% | 3729 |
|
|
2016
Q1 | $900K | Buy |
2,111
+152
| +8% | +$56.9K | ﹤0.01% | 3628 |
|
|
2015
Q4 | $969K | Buy |
1,959
+445
| +29% | +$322K | ﹤0.01% | 3636 |
|
|
2015
Q3 | $1.78M | Buy |
1,514
+97
| +7% | +$149K | ﹤0.01% | 3432 |
|
|
2015
Q2 | $2.5M | Buy |
1,417
+72
| +5% | +$112K | ﹤0.01% | 3327 |
|
|
2015
Q1 | $1.58M | Buy |
1,345
+27
| +2% | +$32K | ﹤0.01% | 3486 |
|
|
2014
Q4 | $1.32M | Buy |
1,318
+16
| +1% | +$16K | ﹤0.01% | 3430 |
|
|
2014
Q3 | $1.76M | Buy |
1,302
+98
| +8% | +$140K | ﹤0.01% | 3318 |
|
|
2014
Q2 | $2.04M | Buy |
1,204
+17
| +1% | +$32.4K | ﹤0.01% | 3257 |
|
|
2014
Q1 | $2.69M | Buy |
1,187
+270
| +29% | +$691K | ﹤0.01% | 3096 |
|
|
2013
Q4 | $1.9M | Buy |
+917
| New | +$1.98M | ﹤0.01% | 3204 |
|
Other funds holding VYNT
Vanguard Group's VYNT Position: Q2 2023 in Review
Vanguard Group sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 47,256 shares — an estimated $27.4K sold.
Vanguard Group first reported a position in VYNT in Q4 2013 and held it in 38 quarters. The position peaked at $3.14M in Q2 2021. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.
- Vanguard Group reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Vanguard Group sold 47,256 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $27.4K.
- Vanguard Group first reported a position in Vyant Bio, Inc. Common Stock in Q4 2013 and held it in 38 quarters.
- Vanguard Group's Vyant Bio, Inc. Common Stock position peaked at $3.14M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.
Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.